Should capmatinib be taken two or four pills per day?

Capmatinib is a targeted therapy drug mainly used to treat MET gene mutation-positive non-small cell lung cancer (NSCLC). According to the latest treatment regimen, the recommended dose of capmatinib is 400 mg twice daily. Therefore, the total daily dose is 800 mg. The following is a detailed introduction to the correct method of taking capmatinib and precautions.

The standard recommended dose of capmatinib is 400mg twice daily for a total dose of 800mg. This dose has been proven in multiple clinical trials to be highly effective in treating patients with MET gene mutation-positive non-small cell lung cancer. By taking the drug twice a day, it can help maintain a stable concentration of the drug in the body, thereby optimizing the efficacy and maximizing the patient's therapeutic effect.

When taking capmatinib, patients should strictly follow the dosage and medication time as directed by their doctor. A twice-daily dosing schedule means patients need to make sure they take their medication on time, morning and evening. If a dose is forgotten, the patient should take it as soon as possible, but if it is close to the next dose, the missed dose should be skipped and the dose should be continued at the normal time. Patients should not increase or decrease the dose of the drug on their own to avoid affecting the therapeutic effect or increasing the risk of side effects.

Capmatinib is not affected by food and can be taken before or after meals. However, some patients may experience gastrointestinal discomfort due to the drug, and it is recommended to take it with food to reduce discomfort. Patients need regular follow-up examinations while taking the medication to monitor the efficacy of the medication and whether side effects occur. Common side effects may include nausea, fatigue, decreased appetite, and abnormal liver function, so patients need to promptly report any adverse reactions to their doctor.

Finally, while taking capmatinib, in addition to taking the drug strictly in accordance with the recommended dosage, patients also need to regularly check liver function, kidney function and other indicators to ensure the safety of drug use. Doctors will conduct regular assessments based on the patient's clinical condition and adjust the treatment plan as needed. In short, capmatinib, as a MET inhibitor, provides an effective treatment option for patients with MET gene mutation-positive non-small cell lung cancer through precise targeted therapy. Reasonable medication regimen and dosage are the key to ensuring its therapeutic effect.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib